Carsten Schou
Directeur/Bestuurslid bij Minervax ApS
Profiel
Carsten Schou is currently the Director at Minervax ApS and the General Partner at SEED Capital Management I.
He previously held positions as Research Director at ALK-Abello A, Director-Biotechnology Research & Innovation at the University of Copenhagen, Director at Celltrix AB, Valderm ApS, Neurokey A, Bok Holding A, OncoTac Pharmaceuticals ApS, EpiTherapeutics ApS, Non-Executive Director at CanImGuide Therapeutics AB, Director at Reapplix A, Acarix AB, Contera Pharma ApS, MedicoSelskabet September 2014 ApS, Acesion Pharma ApS, Galecto Biotech ApS, Evolva A, and Principal at Danske Private Equity A.
He received a graduate degree from the University of Copenhagen and a doctorate degree from Statens Serum Institute.
Actieve functies van Carsten Schou
| Bedrijven | Functie | Begin |
|---|---|---|
SEED Capital Management I/S
 SEED Capital Management I/S Investment ManagersFinance SEED Capital Management I/S is an Independent Venture Capital firm founded in 2004. The company is headquartered in Copenhagen, Denmark. | Private Equity Investor | 01-12-2004 |
Minervax ApS
 Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Carsten Schou
| Bedrijven | Functie | Einde |
|---|---|---|
Valderm ApS
 Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Directeur/Bestuurslid | 21-05-2014 |
OncoTac Pharmaceuticals ApS
 OncoTac Pharmaceuticals ApS Pharmaceuticals: MajorHealth Technology OncoTac Pharmaceuticals ApS develops and commercializes therapeutics for the treatment of cancer diseases. The company was founded by Thomas Senderovitz, John Rømer Nielsen, Charles Pyke, Paul Kristjansen, and Søren Pontoppidan and is headquartered in Copenhagen, Denmark. | Directeur/Bestuurslid | 02-04-2012 |
Neurokey A/S
 Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | Directeur/Bestuurslid | 30-07-2010 |
Acesion Pharma ApS
 Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Directeur/Bestuurslid | - |
| University of Copenhagen | Corporate Officer/Principal | - |
Opleiding van Carsten Schou
| University of Copenhagen | Graduate Degree |
| Statens Serum Institute | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ACARIX AB | Health Technology |
| ALK-ABELLÓ A/S | Health Technology |
| Bedrijven in privébezit | 16 |
|---|---|
SEED Capital Management I/S
SEED Capital Management I/S Investment ManagersFinance SEED Capital Management I/S is an Independent Venture Capital firm founded in 2004. The company is headquartered in Copenhagen, Denmark. | Finance |
Valderm ApS
Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Health Technology |
Bok Holding A/S
 Bok Holding A/S BiotechnologyHealth Technology Bok Holding A/S is a holding company that operates as a biotechnology company that researches and develops cancer treatment solutions. It develops the ZAS platform technology which efficiently enhances the effect of current anti-cancer drugs and reduces toxicity. The firm employs molecular techniques commonly known as molecular breeding or directed enzyme evolution which can activate anti-cancer drugs. The company was founded by Zoran Gojkovic on November 22, 2001 and is headquartered in Gentofte, Denmark. | Health Technology |
OncoTac Pharmaceuticals ApS
OncoTac Pharmaceuticals ApS Pharmaceuticals: MajorHealth Technology OncoTac Pharmaceuticals ApS develops and commercializes therapeutics for the treatment of cancer diseases. The company was founded by Thomas Senderovitz, John Rømer Nielsen, Charles Pyke, Paul Kristjansen, and Søren Pontoppidan and is headquartered in Copenhagen, Denmark. | Health Technology |
Neurokey A/S
Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage. | Health Technology |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Health Technology |
Reapplix A/S
 Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | Distribution Services |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Contera Pharma ApS
 Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
Celltrix AB
 Celltrix AB Medical SpecialtiesHealth Technology Celltrix AB manufactures medical devices. It develops novel and injectable dermal filler for reconstructive cosmetic surgery, based on microbeads of cross-linked gelatine. The company was founded in December 2003 by Kjell Gösta Conny Nilsson and is headquartered in Malmö, Sweden. | Health Technology |
MedicoSelskabet September 2014 ApS
 MedicoSelskabet September 2014 ApS Medical SpecialtiesHealth Technology MedicoSelskabet September 2014 ApS is a holding company that develops medical devices for cardiovascular sensing. Its scheme is based on a concept that does not interfere with the state of the patient. It improves the method of measuring hypertension and suitable for ambulatory continuous measurements. Its also involves in the repair of communication equipment. The company was founded by Ole Kjerulf Jensen and Lars Lading on June 14, 2002 and is headquartered in Hellerup, Denmark. | Health Technology |
Danske Private Equity A/S
 Danske Private Equity A/S Investment ManagersFinance Danske Private Equity A/S (DPE) is a private equity fund of funds investment firm founded in 1999. The firm is headquartered in Lyngby. | Finance |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
Acesion Pharma ApS
Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
| Evolva A/S | |
CanImGuide Therapeutics AB
 CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Health Technology |
